Genentech's Phase III REGENCY trial demonstrates that Gazyva plus standard therapy achieved 46.4% complete renal response in lupus nephritis patients compared to 33.1% with standard therapy alone.
Genentech's Gazyva met its primary endpoint in a Phase III REGENCY study, demonstrating statistically significant benefits for lupus nephritis patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.